D2M Biotherapeutics Inc.
1 clinical trials · Sponsor
◉ Watch D2M Biotherapeutics Inc.
| Record | Firm | Date |
|---|---|---|
| A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (NCT06328673) | D2M Biotherapeutics Inc. | 2024-04-09 |
Track D2M Biotherapeutics Inc. automatically
Every clearance here is in the API, with alerts when new ones post.